Retreatment With R-CHOP-Like Therapy Yields Durable Remission in Late-Relapse DLBCL
Jean-Nicolas Champagne, MD, BC Cancer Vancouver, Canada, discusses results from a retrospective study that evaluated outcomes of patients treated with R-CHOP-like therapy for late-relapse diffuse large B-cell lymphoma (DLBCL) in British Columbia. The study found that retreatment with R-CHOP-like therapy was a reasonable option for this patient population and resulted in durable remission in a high proportion of patients.
Dr Champagne presented these results at the 66th ASH Annual Meeting in San Diego, California.
Source:
Champagne JN, Villa D, Gerrie A, et al. Retreatment with R-CHOP-like therapy in patients with late relapse of diffuse large b-cell lymphoma (DLBCL). Presented at 66th ASH Annual Meeting & Exposition; December 7-10, 2024; San Diego, California. Abstract 109.
© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of LL&M, Oncology Learning Network or HMP Global, their employees, and affiliates.
